###begin article-title 0
Adaptive Mutations in the JC Virus Protein Capsid Are Associated with Progressive Multifocal Leukoencephalopathy (PML)
###end article-title 0
###begin p 1
Conceived and designed the experiments: LG. Performed the experiments: KS LG. Analyzed the data: SRS AL LG. Contributed reagents/materials/analysis tools: SRS AL KS. Wrote the paper: SRS AL LG.
###end p 1
###begin p 2
###xml 70 78 <span type="species:ncbi:10632">JC virus</span>
###xml 191 199 <span type="species:ncbi:10632">JC virus</span>
###xml 227 232 <span type="species:ncbi:9606">human</span>
###xml 378 381 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 383 387 <span type="species:ncbi:12721">AIDS</span>
###xml 655 663 <span type="species:ncbi:10632">JC virus</span>
###xml 750 758 <span type="species:ncbi:9606">patients</span>
###xml 942 950 <span type="species:ncbi:10632">JC virus</span>
###xml 1043 1051 <span type="species:ncbi:10632">JC virus</span>
###xml 1087 1095 <span type="species:ncbi:9606">patients</span>
###xml 1318 1326 <span type="species:ncbi:10632">JC virus</span>
###xml 1416 1424 <span type="species:ncbi:10632">JC virus</span>
###xml 1771 1779 <span type="species:ncbi:10632">JC virus</span>
PML is a progressive and mostly fatal demyelinating disease caused by JC virus infection and destruction of infected oligodendrocytes in multiple brain foci of susceptible individuals. While JC virus is highly prevalent in the human population, PML is a rare disease that exclusively afflicts only a small percentage of immunocompromised individuals including those affected by HIV (AIDS) or immunosuppressive drugs. Viral- and/or host-specific factors, and not simply immune status, must be at play to account for the very large discrepancy between viral prevalence and low disease incidence. Here, we show that several amino acids on the surface of the JC virus capsid protein VP1 display accelerated evolution in viral sequences isolated from PML patients but not in sequences isolated from healthy subjects. We provide strong evidence that at least some of these mutations are involved in binding of sialic acid, a known receptor for the JC virus. Using statistical methods of molecular evolution, we performed a comprehensive analysis of JC virus VP1 sequences isolated from 55 PML patients and 253 sequences isolated from the urine of healthy individuals and found that a subset of amino acids found exclusively among PML VP1 sequences is acquired via adaptive evolution. By modeling of the 3-D structure of the JC virus capsid, we showed that these residues are located within the sialic acid binding site, a JC virus receptor for cell infection. Finally, we go on to demonstrate the involvement of some of these sites in receptor binding by demonstrating a profound reduction in hemagglutination properties of viral-like particles made of the VP1 protein carrying these mutations. Collectively, these results suggest that a more virulent PML causing phenotype of JC virus is acquired via adaptive evolution that changes viral specificity for its cellular receptor(s).
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 0 8 <span type="species:ncbi:10632">JC virus</span>
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 162 168 <span type="species:ncbi:9606">people</span>
###xml 1269 1277 <span type="species:ncbi:10632">JC virus</span>
JC virus is a highly prevalent human polyomavirus. Infection with this virus is generally benign and asymptomatic despite viral persistence in the kidney of many people. However, in immunocompromised individuals, very rarely, the infection can progress to become a potentially deadly brain disease called Progressive Multifocal Leukoencephalopathy (PML). The discrepancy between very high viral prevalence and low incidence of PML suggests that there could be some unique viral characteristics that regulate the progression from the asymptomatic infection to the PML. Identification of such factors will help us to understand the basis of PML development and hopefully will lead to the creation of new diagnostic and treatment tools for managing PML. In this work, we demonstrate that the part of the viral surface protein that is thought to be responsible for viral interaction with cellular receptors and infection acquires specific mutations that appear to be critical for the development of PML. These mutations are found more frequently than by simple chance and therefore are thought to be "positively selected." Based on these results, we hypothesize that the specific mutations in the viral VP1 protein that we have identified are critical for the evolution of JC virus to the version associated with PML.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 214 217 214 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Knowles1">[1]</xref>
###xml 793 796 793 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Berger1">[2]</xref>
###xml 860 863 860 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-GarciaSuarez1">[3]</xref>
###xml 0 8 <span type="species:ncbi:10632">JC virus</span>
###xml 10 13 <span type="species:ncbi:10632">JCV</span>
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 76 82 <span type="species:ncbi:9606">people</span>
###xml 96 99 <span type="species:ncbi:10632">JCV</span>
###xml 328 333 <span type="species:ncbi:9606">human</span>
###xml 422 425 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 518 521 <span type="species:ncbi:10632">JCV</span>
###xml 686 694 <span type="species:ncbi:10632">JC virus</span>
###xml 751 759 <span type="species:ncbi:9606">patients</span>
###xml 779 783 <span type="species:ncbi:12721">AIDS</span>
###xml 784 792 <span type="species:ncbi:9606">patients</span>
###xml 817 825 <span type="species:ncbi:9606">patients</span>
###xml 949 956 <span type="species:ncbi:9606">patient</span>
###xml 1003 1010 <span type="species:ncbi:9606">patient</span>
###xml 1046 1050 <span type="species:ncbi:12721">AIDS</span>
JC virus (JCV) is highly prevalent in the human population with over 70% of people showing anti-JCV antibody responses and up to 40% of the population displaying persistent viral shedding in the urine (reviewed in [1]). These epidemiological data indicate that the virus establishes chronic infection in a large fraction of the human population. Though normally asymptomatic, factors leading to immune deficiency, such as HIV or immunosuppressive drug therapy, can trigger an uncontrolled infection and replication of JCV in oligodendrocytes causing their death and resulting in progressive multifocal leukoencephalopathy (PML). Despite such a high infection rate and viral occurrence, JC virus causes PML in a very small fraction of immune deficient patients, including 4-5% of AIDS patients [2] and less than 1% of patients with lymphoproliferative diseases [3]. No pharmaceutical treatment option for PML currently exists and the only chance for patient survival is afforded by reconstitution of the patient's own immune response via HAART in AIDS or via drug tapering in pharmaceutically immunocompromised individuals. Identification of genetic and environmental risk factors influencing the development of PML is of great importance both for finding of therapeutic interventions and for the development of early diagnostic methods to help reducing the risks associated with immunosuppressive therapies.
###end p 6
###begin p 7
###xml 190 193 190 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Pfister1">[4]</xref>
###xml 194 197 194 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Zheng1">[8]</xref>
###xml 317 320 317 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Zheng1">[8]</xref>
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Kato1">[10]</xref>
###xml 500 504 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Srinivasan1">[11]</xref>
###xml 505 509 505 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Chandrasekaran1">[12]</xref>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Bauer1">[13]</xref>
###xml 541 545 541 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Bauer2">[14]</xref>
###xml 1078 1082 1078 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Dubensky1">[15]</xref>
###xml 1083 1087 1083 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Freund1">[16]</xref>
###xml 281 289 <span type="species:ncbi:10632">JC virus</span>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
###xml 409 417 <span type="species:ncbi:10632">JC virus</span>
###xml 517 535 <span type="species:ncbi:10634">mouse polyomavirus</span>
###xml 567 572 <span type="species:ncbi:9606">human</span>
###xml 573 576 <span type="species:ncbi:10632">JCV</span>
###xml 907 925 <span type="species:ncbi:10634">mouse polyomavirus</span>
Both host and viral genetics may contribute to PML. Earlier studies focusing on viral genetic factors identified duplications and rearrangements in the regulatory region of the viral genome [4]-[8]. Several studies also reported presence of several mutations in VP1 protein in the JC virus isolated from PML patients [8]-[10]. No comprehensive analysis of an association of changes in protein coding genes of JC virus with PML has been reported. Pathogenicity of viruses ranging from influenza virus [11],[12] to the mouse polyomavirus [13],[14], a close relative of human JCV, was shown to be determined by amino acid sequences involved in the binding of a viral capsid protein to sialylated glycan receptors. Changes in the affinity and specificity of the virus for its cellular receptor(s) affect viral infectivity and transmission, hence playing a crucial role in virulence. For example, a study of the mouse polyomavirus showed that VP1 amino acid changes rather than changes in the non-coding regulatory region are responsible for the increased pathogenicity of the virus [15],[16].
###end p 7
###begin p 8
Consequently, we focused on VP1 protein and its relationship to PML. We relied on methods of molecular evolution to determine the presence of putative adaptive changes in the VP1 amino acid sequence associated with PML. The advantage of this approach over simple statistical association of sequence variants with the disease, is that it takes into account the phylogenetic relationship of viral strains and also allows identification of functionally significant amino acid positions by examining the rate of sequence evolution.
###end p 8
###begin title 9
Results/Discussion
###end title 9
###begin p 10
###xml 4 7 4 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 53 61 53 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000368.s002">Table S1</xref>
###xml 234 243 234 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000368-g001">Figure 1A</xref>
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Guindon1">[17]</xref>
###xml 323 327 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Kishino1">[18]</xref>
###xml 328 332 328 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Felsenstein1">[19]</xref>
###xml 703 712 703 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000368-g001">Figure 1A</xref>
###xml 792 793 792 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 802 806 802 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Slatkin1">[20]</xref>
###xml 842 845 842 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Zheng1">[8]</xref>
###xml 846 850 846 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Jobes1">[21]</xref>
###xml 851 855 851 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Agostini1">[22]</xref>
###xml 0 3 <span type="species:ncbi:10632">JCV</span>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 569 577 <span type="species:ncbi:9606">patients</span>
JCV VP1 gene sequences were downloaded from GenBank (Table S1) and used to construct a phylogenetic tree for a random subset of sequences isolated from healthy individual and full-length sequences isolated from distinct PML patients (Figure 1A). We used the PhyML maximum likelihood method [17] with F84 substitution model [18],[19]. Application of several methods incorporated in the PHYLIP package such as maximum likelihood method, distance-based and parsimony-based methods of phylogenetic reconstruction produced similar results. Viral sequences isolated from PML patients do not cluster on the phylogenetic tree and are broadly distributed among viral types and geographic origins of the samples (Figure 1A). This is further supported by the Slatkin-Maddison test for group separation (p = 0.38) [20]. In agreement with earlier studies [8],[21],[22], PML causing viruses are not limited to a specific viral phylogenetic type.
###end p 10
###begin title 11
Phylogenetic distribution of PML associated viruses.
###end title 11
###begin p 12
###xml 279 282 279 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 446 449 446 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 343 350 <span type="species:ncbi:9606">patient</span>
###xml 509 517 <span type="species:ncbi:9606">patients</span>
(A) Broad phylogenetic distribution of PML causing JC viruses. Tree branches (labeled by GI numbers) corresponding to PML causing viruses are marked by red stars, viruses isolated from healthy subjects are marked by green stars. The tree is constructed based on DNA sequences of VP1 gene using maximum likelihood method. Only one sequence per patient was included. (B) Phylogenetic distribution of mutations in the codon 269. The tree represents VP1 genes (labeled by GI numbers) of viruses isolated from PML patients. Mutations in Ser269 codons are indicated by text inserts. Circles on branches reflect aLRT support. Position 269 was masked prior to constructing the tree to avoid attraction of branches with mutations of this codon.
###end p 12
###begin p 13
###xml 214 217 214 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 264 268 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Yang1">[23]</xref>
###xml 743 750 743 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000368-t001">Table 1</xref>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Next, we analyzed sequences from viruses isolated from PML patients as well as those from healthy subjects with the goal of determining whether PML associated evolutionary selective pressure is acting on the viral VP1 gene. This analysis utilized the PAML package [23] designed to identify the presence of codons evolving under positive selection. PAML evaluates multiple evolutionary models using the parametric likelihood ratio test. We tested several models including a model of neutral evolution, a nearly neutral model allowing for purifying (i.e. negative) selection, and a heterogeneous model that allows some codon positions to evolve under positive selection and other codon positions to evolve under negative selection or neutrally (Table 1). We also tested a number of more complex models.
###end p 13
###begin title 14
Codons under positive selection in the PML sample.
###end title 14
###begin p 15
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Yang1">[23]</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
VP1 sequences isolated from PML patients and random subsets of sequences isolated from healthy subjects were further analyzed using PAML [23]. We examined multiple models of sequence evolution incorporated in PAML including purely neutral model (M0), nearly neutral model (M1), model with positive selection (M2) and additional more complex models (M3-M8). We used likelihood ratio test (LRT) to compare the difference between models M1 and M2 to test for positive selection. P-values for positive selection in three datasets are shown together with Bayesian posterior probabilities for each codon position. Residues with Bayes Empirical Bayes posterior probabilities exceeding 0.5 are shown.
###end p 15
###begin p 16
###xml 15 18 15 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 241 242 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 255 257 255 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 385 388 385 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 545 552 545 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000368-t001">Table 1</xref>
###xml 838 839 838 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 852 854 852 854 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 34 37 <span type="species:ncbi:10632">JCV</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
In the case of VP1 sequences from JCV isolated from healthy subjects, the nearly neutral evolutionary model involving a mixture of neutrally evolving codons and codons under purifying selection clearly outperformed the purely neutral model (p-value 7.0x10-6). However, no statistical support was found for more complex models including models with positive selection. In contrast, for VP1 sequences isolated from PML patients, allowing codons to evolve under positive selection resulted in a highly significant increase in the model likelihood (Table 1). The model with three categories of sites including sites evolving under purifying selection, neutral sites and sites under positive selection explained the data significantly better than the nearly neutral model limited only to neutral sites and the sites under purifying selection (p-value 2.5x10-7). More complex models did not show significant improvement over the simplest model with three categories of codons.
###end p 16
###begin p 17
###xml 171 178 171 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000368-t001">Table 1</xref>
###xml 426 429 426 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 568 575 568 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000368-t001">Table 1</xref>
###xml 445 453 <span type="species:ncbi:10632">JC virus</span>
###xml 472 480 <span type="species:ncbi:9606">patients</span>
Four codon positions (corresponding to amino acids 55, 60, 267 and 269) were identified as evolving under positive selection in the PML sampling of full length sequences (Table 1). Bayesian posterior probabilities for positive selection computed by PAML were above 0.5 for these codon positions. The posterior probability for positive selection in codon 269 was close to 1. To increase the power of analysis, we added partial VP1 sequences from JC virus isolated from PML patients. The addition of partial sequences revealed signal of positive selection in codon 265 (Table 1).
###end p 17
###begin p 18
###xml 37 40 37 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Poon1">[24]</xref>
###xml 63 66 <span type="species:ncbi:10632">JCV</span>
Interestingly, we never observed two VP1 mutations in the same JCV isolate. Analysis by the Spidermonkey [24] method revealed epistatic interactions between positions 55 and 269 and between position 60 and 269 (with posterior probabilities 0.88 and 0.70 respectively). This may reflect "diminishing return" epistatic interactions, i.e. subsequent mutations are not beneficial and possibly detrimental on the background of a single mutation.
###end p 18
###begin p 19
###xml 334 342 334 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000368.s003">Table S2</xref>
###xml 470 479 470 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000368-g001">Figure 1B</xref>
###xml 597 600 597 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 907 911 907 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Guindon1">[17]</xref>
###xml 1049 1053 1049 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Jobes1">[21]</xref>
###xml 1054 1058 1054 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Agostini1">[22]</xref>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 998 1006 <span type="species:ncbi:10632">JC virus</span>
All substitutions in these five codons are clearly associated with PML. At least 52% of JC viruses (or 36 out of 69 sequences, including partial sequences) isolated from PML patients have at least one of these mutations, whereas none of these substitutions have been observed in 253 full length viral sequences from healthy subjects (Table S2). The strongest signal of positive selection in the PML sample was detected for the codon encoding amino acid at position 269. Figure 1B shows that multiple independent mutations of Ser269 to aromatic residues phenylalanine and tyrosine were observed in VP1 from PML associated viruses. The existence of multiple independent mutations is not an artifact of phylogenetic reconstruction because lineages with mutant variants are separated by multiple branches with over 90% support by bootstrap analysis and support of the likelihood ratio test implemented in PhyML [17]. These lineages correspond to different, previously identified, phylogenetic types of JC virus and are from diverse geographic locations [21],[22].
###end p 19
###begin p 20
###xml 309 313 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Stehle1">[25]</xref>
###xml 345 354 334 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000368-g002">Figure 2A</xref>
###xml 858 862 847 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Srinivasan1">[11]</xref>
###xml 863 867 852 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Bauer2">[14]</xref>
###xml 868 872 857 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Nam1">[26]</xref>
###xml 1019 1023 1008 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Bauer1">[13]</xref>
###xml 1193 1202 1182 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000368-g002">Figure 2B</xref>
###xml 144 152 <span type="species:ncbi:10632">JC virus</span>
###xml 815 833 <span type="species:ncbi:10634">mouse polyomavirus</span>
###xml 839 844 <span type="species:ncbi:10090">mouse</span>
###xml 905 923 <span type="species:ncbi:10634">mouse polyomavirus</span>
###xml 949 957 <span type="species:ncbi:10632">JC virus</span>
###xml 1067 1072 <span type="species:ncbi:9606">human</span>
###xml 1073 1081 <span type="species:ncbi:10632">JC virus</span>
###xml 1222 1227 <span type="species:ncbi:9606">human</span>
###xml 1228 1236 <span type="species:ncbi:10632">JC virus</span>
###xml 1259 1277 <span type="species:ncbi:10634">mouse polyomavirus</span>
To get an insight into a functional role of the five identified amino acid positions, we constructed a three-dimensional molecular model of the JC virus VP1 bound to NeuNAc-(alpha2,3)-Gal-(beta1,3)-[(alpha2,6)-NeuNAc]-Glc-NAc tetrasaccharide based on the crystal structure of MPyV VP1/oligosaccharide complex [25]. The structural model shown in Figure 2A suggests that all PAML-identified amino acids are clustered on the surface of the VP1 protein at the sialic acid binding site and are likely to be involved in sialic acid binding. Additionally, we predicted that L55F, K60M, S267F, and S269F substitutions may induce steric clashes with the modeled saccharide leading to a decrease in the affinity of the interaction. Affinity to sialic acid was related to viral pathogenicity in multiple studies of flu virus, mouse polyomavirus, and mouse minute virus [11]-[14],[26]. Particularly, pathogenicity of mouse polyomavirus, a close relative of the JC virus, was mapped to a VP1 amino acid substitution at position 296 [13], a position orthologous to position 269 in human JC virus that showed the strongest signal of positive selection in PML-causing viral isolates in our study. As shown in Figure 2B, serine 269 of the human JC virus and valine 296 of the mouse polyomavirus occupy identical locations in the sialic acid binding pocket.
###end p 20
###begin title 21
###xml 20 23 <span type="species:ncbi:10632">JCV</span>
Structural model of JCV VP1/NeuNAc-(alpha2,3)-Gal-(beta1,3)-[(alpha2,6)-NeuNAc]-Glc-NAc tetrasaccharide complex.
###end title 21
###begin p 22
###xml 321 328 310 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000368-t001">Table 1</xref>
###xml 430 438 419 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000368.s003">Table S2</xref>
###xml 15 18 <span type="species:ncbi:10632">JCV</span>
###xml 158 161 <span type="species:ncbi:10632">JCV</span>
###xml 597 600 <span type="species:ncbi:10632">JCV</span>
###xml 737 740 <span type="species:ncbi:10632">JCV</span>
(A) A model of JCV VP1 basic pentamer in complex with NeuNAc-(alpha2,3)-Gal-(beta1,3)-[(alpha2,6)-NeuNAc]-Glc-NAc tetrasaccharide. Surfaces of five chains of JCV VP1 are shown in different colors. The RG motif essential for binding of core sialic acid is shown in blue. PML-associated mutated residues confirmed by PAML (Table 1) are shown in red (L55, K60, S265, S267, S269). Additional mutations unique to PML-isolated samples (Table S2) are shown in green (S61, D66, S123, H129, V223 and Q271). (B) A close-up view of NeuNAc-(alpha2,3)-Gal-(beta1,3)-[(alpha2,6)-NeuNAc]-Glc-NAc tetrasaccharide/JCV VP1 complex. The color scheme is as described in panel (A). Location of V296 of MPyV VP1 which is predicted to be equivalent to S269 of JCV VP1 is shown in yellow mesh.
###end p 22
###begin p 23
###xml 88 96 88 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000368.s003">Table S2</xref>
###xml 152 161 152 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000368-g002">Figure 2B</xref>
###xml 516 520 516 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Anisimova1">[27]</xref>
###xml 521 525 521 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Anisimova2">[28]</xref>
###xml 617 621 617 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Anisimova1">[27]</xref>
###xml 678 682 678 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Anisimova2">[28]</xref>
We note that positions 61, 66, 123, 129, 223 and 271 are all limited to the PML sample (Table S2) and also line up with the sialic acid binding pocket (Figure 2B). It is possible that those residues went undetected by the PAML analysis due to the small sample size and that the development of PML is accompanied by positive selection for amino acids involved in sialic acid binding in a majority of cases. The length of the phylogenetic tree in our analysis is short thus limiting power to detect positive selection [27],[28]. Likelihood ratio test for detecting positive selection using a short tree is conservative [27], and Bayes Empirical Bayes analysis is of limited power [28]. Thus, additional PML-specific VP1 mutations can also be positive selected. Mutations at residue 107 are also found exclusively in the PML sample. However, it did not show evidence of positive selection according to PAML and is not located in the sialic acid binding pocket.
###end p 23
###begin p 24
###xml 272 275 272 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 526 529 526 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 682 690 682 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000368.s004">Table S3</xref>
###xml 823 827 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Freund1">[16]</xref>
###xml 828 832 828 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Liu1">[29]</xref>
###xml 999 1006 999 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000368-t002">Table 2</xref>
###xml 1887 1895 1879 1887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000368.s004">Table S3</xref>
###xml 1900 1908 1892 1900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000368.s003">Table S2</xref>
###xml 2032 2036 2024 2028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Padgett1">[30]</xref>
###xml 665 672 <span type="species:ncbi:9606">patient</span>
###xml 1072 1077 <span type="species:ncbi:9606">human</span>
###xml 2024 2031 <span type="species:ncbi:9606">patient</span>
In order to experimentally verify the role that these substitutions play in sialic acid binding by the VP1 capsid, we recombinantly produced viral like particles (VLP) from VP1 protein encoded by several different naturally occurring viruses. We generated VLPs from viral VP1 sequences encoding substitutions with one of the two strongest signals of positive selection identified by PAML, one with phenylalanine at position 269 (F269) and another one with phenylalanine at position 55 (F55). As controls we used two different VP1 genes that do not harbor any of the identified PML-associated mutations, one from a healthy individual (WT) and another one from a PML patient (Mad-1) (Table S3). Viral hemagglutination of red blood cells (RBCs) has been shown to be a reliable measure of sialic acid binding by polyomaviruses [16],[29]. We tested all four VLPs in a hemagglutination assay. Strikingly, both F55 and F269 variants displayed more than 8000-fold lower HA activity than either control VLP (Table 2). Specifically, the F55 variant completely failed to agglutinate human type O RBCs even at 200 microg/ml, the highest concentration tested, and the F269 variant displayed very low HA activity as it caused hemagglutination only at concentrations above 25 microg/ml. At the same time both L55 and S269 carrying variants (WT and Mad-1) caused hemagglutination of RBCs at concentrations down to 0.375 ng/ml and 6.25 ng/ml, correspondingly. We note that the F55 mutant has the single amino acid difference with its corresponding wild type variant (WT). Therefore the change in hemagglutination can be specifically attributed to this amino acid replacement. In addition to the change in position 269 the F269 mutant variant has two additional amino acid positions that are different from its corresponding control variant (Mad-1). Both of those amino acid changes are not PML specific (Table S3 and Table S2) and are unlikely to explain the difference in hemagglutination. While the Mad-1 isolate had originated from a PML patient [30] it does not contain any of the PML-specific mutation which correlates well with its ability to hemagglutinate RBCs. The lack of PML-genic mutations in this PML isolate suggests that VP1 mutations are not an exclusive mechanism leading to PML development.
###end p 24
###begin title 25
Residues 55 and 269 in VP1 protein play very important role in hemagglutination of RBCs by Viral Like Particles (VLPs).
###end title 25
###begin p 26
###xml 47 68 47 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Materials and Methods</xref>
Hemagglutination was conducted as described in Materials and Methods using serial dilutions of VLPs starting from 200 microg/ml. VLPs were added to type O RBC and incubated at 4degreesC for 3 hours. Agglutination is visualized by the lack of a round pellet formed by the settling of RBCs out of suspension. F55 is a VP1 variant with phenylalanine at the position 55 (AAT09831), F269 is a VP1 variant with phenylalanine at the position 269 (BAE0011). WT (AAQ88264) and Mad-1 (P03089) are VP1 variants with leucine and serine at positions 55 and 269 respectively.
###end p 26
###begin p 27
###xml 98 104 98 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">per se</italic>
###xml 985 989 985 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Dubensky1">[15]</xref>
###xml 990 994 990 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Freund1">[16]</xref>
###xml 1109 1113 1109 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Kato2">[31]</xref>
###xml 1114 1118 1114 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Monaco1">[32]</xref>
###xml 1365 1369 1365 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Eash1">[33]</xref>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 361 364 <span type="species:ncbi:10632">JCV</span>
###xml 755 773 <span type="species:ncbi:10634">mouse polyomavirus</span>
###xml 842 845 <span type="species:ncbi:10632">JCV</span>
###xml 1038 1041 <span type="species:ncbi:10632">JCV</span>
###xml 1177 1180 <span type="species:ncbi:10632">JCV</span>
###xml 1317 1320 <span type="species:ncbi:10632">JCV</span>
Although we do not know at the moment how these amino acid substitutions affect viral infectivity per se, it is reasonable to assume that a virus harboring such substitutions is adequately infectious as it was sufficiently abundant in the CNS of PML patients to be isolated. Therefore, it is tempting to speculate that changes in glycan specificity would allow JCV to loose its specificity to sialated glycans expressed outside of the CNS (e.g. RBCs). Thus, such a virus would avoid getting trapped on "pseudoreceptors" in the periphery and travel unhindered from sites of viral shedding to enter the brain. Mutated virus must still maintain its specificity to glycans expressed on oligodendrocytes. This would be consistent with the observation from the mouse polyomavirus model where a mutation in a position orthologous to position 269 of JCV affected viral ability to bind RBCs and also lead to the dramatic increase in viral dissemination through the animal with a lethal outcome [15],[16]. Furthermore, there are several reports of JCV detection in tonsils of many asymptomatically infected individuals [31],[32]. Although this observation was taken as a support for the JCV infection of tonsil cells, it could be alternatively explained by the viral trapping in lymphoid tissues. That would be consistent with JCV binding to sialic acid in the tonsil tissue [33].
###end p 27
###begin p 28
###xml 82 85 82 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 105 108 <span type="species:ncbi:10632">JCV</span>
An alternative but not mutually exclusive hypothesis would be that PML associated VP1 mutations increase JCV tropism for brain white matter cells leading to the increased viral infectivity and replication in oligodendrocytes. Finally, another non-mutually exclusive explanation of the role these mutations in PML might be immune-escape by the virus. It is theoretically possible that out of the polyclonal immune response directed against the VP1 molecule only a limited number of antibodies directed against the cell receptor binding site (i.e. sialic acid) would provide protection against the spread of the viral infection. Mutation of an amino acid within an epitope crucial for the protective immunity could allow virus to bind to its target cells and spread uninhibited. Given the large number of mutations that are specific for PML it is likely that not a single mechanism but rather a multiplicity plays a role in PML etiology in different PML cases.
###end p 28
###begin p 29
###xml 485 488 485 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Loeber1">[6]</xref>
###xml 1113 1116 1113 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 1383 1386 1383 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Loeber1">[6]</xref>
###xml 79 82 <span type="species:ncbi:10632">JCV</span>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 595 602 <span type="species:ncbi:9606">patient</span>
###xml 1932 1940 <span type="species:ncbi:9606">patients</span>
###xml 1964 1967 <span type="species:ncbi:10632">JCV</span>
How do these mutations occur in PML and why, despite a very high prevalence of JCV, do only a small proportion of immune deficient patients develop PML? Absence of clustering of the mutations on the viral phylogenetic tree suggests that they arise independently in individual patients rather than persist in the general populations as pathogenic viral variants. It is worth noting that this hypothesis appears to be strongly supported by the original observation of Loeber and Dorries [6] where the investigators reported the isolation of two viral strains from kidney and brain of the same PML patient. The genome of the virus isolated from the brain was almost identical to that isolated from the kidney with two exceptions; presence of phenylalanine instead of leucine in position 55 and a rearrangement of the regulatory region. Previously no significance could be attached to the L55F mutation and that observation led to the generation of the hypothesis on the sole importance of viral control region rearrangement in "PML-genic" adaptation of the virus. Based on our findings we would like to propose that VP1 mutations play a very significant role in the mechanism of PML emergence. Once a specific mutation affecting sialic acid binding occurs it allows virus to spread to the brain and infect oligodendrocytes. The fact that the mutant virus was not detected in the kidney [6] may suggest that that particular change in glycan binding does not offer any selective advantage to the mutated virus in kidney. The mutations might have occurred and hence allowed the virus to establish the residence in the brain under the conditions of immune suppression shortly or long before the PML. Since no viral replication was detected in brains of asymptomatic individuals we believe it is unlikely that compartmentalized evolution (i.e. intra CNS) prior to PML development could account for the presence of mutated VP1 in CNS of PML patients. However, the issue of JCV latency in normal brain still remains controversial so it is still formally possible that non-mutated virus had entered the brain and mutations arose in the brain and not periphery, e.g. kidney.
###end p 29
###begin p 30
###xml 719 722 719 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
It appears that the healthy immune system effectively controls viral activation in the brain. However, as soon as the immune system fails in the misfortunate individual harboring such a mutated virus, the virus begins actively proliferating in oligodendrocytes causing PML. It is also possible that a healthy immune system efficiently suppresses newly developed mutants in their peripheral site (e.g. kidney) and prevents them from spreading and infecting new target cells. Thus the timing of PML development may be mutation limited and the interplay with environmental or host genetic factors contributed to the non-deterministic development of PML. Alternatively, PML development may be controlled by interactions of VP1 mutations with additional genetic alterations of the virus including rearrangement of the viral regulatory region as it might give the virus additional selective advantage in increasing viral replication in oligodendrocytes.
###end p 30
###begin p 31
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 37 40 <span type="species:ncbi:10632">JCV</span>
###xml 559 567 <span type="species:ncbi:9606">patients</span>
Altogether our findings suggest that JCV VP1 mutations affecting its receptor specificity may be responsible for PML pathology. These results pave the way for the discovery of novel anti-polyomavirus therapeutics and diagnostics of diseases caused by these viruses. The exact role that these mutations play in etiology of PML as well as how and where they arise requires further extensive investigation that would involve VP1 sequence analysis of longitudinal and time matching samples from different organs (e.g. urine, blood, CSF) and from a variety of PML patients.
###end p 31
###begin title 32
Materials and Methods
###end title 32
###begin title 33
Sequence Analysis
###end title 33
###begin p 34
###xml 15 18 15 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 90 93 90 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 203 206 203 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 383 391 383 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000368.s002">Table S1</xref>
###xml 497 501 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Sala1">[34]</xref>
###xml 638 646 638 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000368.s002">Table S1</xref>
###xml 781 785 781 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Notredame1">[35]</xref>
###xml 1145 1148 1143 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 1174 1177 1172 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 1289 1297 1287 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000368.s002">Table S1</xref>
###xml 1371 1375 1369 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Guindon1">[17]</xref>
###xml 1404 1408 1402 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Kishino1">[18]</xref>
###xml 1409 1413 1407 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Felsenstein1">[19]</xref>
###xml 1514 1539 1512 1537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Distributed by the author</italic>
###xml 1541 1570 1539 1568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Department of Genome Sciences</italic>
###xml 1572 1596 1570 1594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">University of Washington</italic>
###xml 1598 1605 1596 1603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Seattle</italic>
###xml 1608 1611 1606 1609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP1</italic>
###xml 1745 1749 1743 1747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Yang1">[23]</xref>
###xml 2055 2062 2053 2060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000368-t001">Table 1</xref>
###xml 2085 2089 2083 2087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Poon1">[24]</xref>
###xml 2179 2183 2177 2181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Pond1">[36]</xref>
###xml 2310 2314 2308 2312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Slatkin1">[20]</xref>
###xml 2375 2379 2373 2377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Pond2">[37]</xref>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
###xml 552 560 <span type="species:ncbi:9606">patients</span>
###xml 922 929 <span type="species:ncbi:9606">patient</span>
###xml 1206 1214 <span type="species:ncbi:9606">patients</span>
###xml 1640 1648 <span type="species:ncbi:9606">patients</span>
35 full length VP1 sequences of JC viruses isolated from PML patients and 253 full length VP1 sequences of JC viruses isolated from healthy subjects were downloaded from Genbank. In addition, 20 partial VP1 sequences were available from Genbank enabling the analysis of the total of 55 sequences for positions 43-287. In addition to these 55 VP1 sequences isolated from PML patients Table S1 also contains information from twelve more partial sequences available from a publication by Sala et al. [34]. We note that all viral samples isolated from PML patients originated from brain or CSF tissues except one sample isolated from kidney (Table S1). All viral samples isolated from healthy subjects originated from urine. Multiple sequence alignments were constructed using TCoffee [35]. A number of PML sequences were isolated from the same individual. Since we were studying evolution of viral sequences we accepted same patient isolated sequences for our analysis as long as they differed from each other by >/=1 nucleotide. However, we excluded identical "clonal" sequences from our analysis. This resulted in the final set of 28 full-length VP1 sequences and 42 partial VP1 sequences isolated from PML patients. All information on the origin and clonality of sequences is contained in Table S1. Phylogenetic trees were built using the PhyML maximum likelihood method [17] with F84 substitution model [18],[19] and using several methods included in the PHYLIP package (Felsenstein, J. 2005. PHYLIP version 3.6. Distributed by the author. Department of Genome Sciences, University of Washington, Seattle). VP1 sequences isolated from PML patients and random subsets of sequences isolated from healthy subjects were further analyzed using PAML [23]. We examined multiple models of sequence evolution (M0-M8). We used likelihood ratio test for difference between models M1 and M2 to test for positive selection. Residues with Bayes Empirical Bayes posterior probabilities exceeding 0.5 in the analysis of either full-length or partial set are reported in Table 1. We used Spidermonkey [24] to analyze epistatic interaction. Spidermonkey was run through the Datamonkey web server [36]. Slatkin-Maddison test was used to evaluate separation of PML-casing JC viruses and JC viruses isolated from healthy subjects [20]. We used HyPhy package to compute the Slatkin-Maddison test [37]. The significance of group separation was determined using the permutation test (1000 permutations).
###end p 34
###begin title 35
Hemagglutination Assay
###end title 35
###begin p 36
###xml 61 65 61 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Chapagain1">[38]</xref>
###xml 66 70 66 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Padgett2">[39]</xref>
###xml 81 86 <span type="species:ncbi:9606">human</span>
Hemagglutination assay was performed as previously described [38],[39]. Briefly, human type O blood was washed twice and suspended in Alsever's buffer (20 mM sodium citrate, 72 mM NaCl, 100 mM glucose, pH 6.5 adjusted with acetic acid) at a final concentration of approximately0.5%. Serial two-fold dilutions of VLPs were prepared in Alsever's buffer and an equal volume of RBCs was added into each well of a 96-well "U" bottom microtiter plate and incubated at 4degreesC for 3-6 hr. Minimum HA concentration is the lowest concentration of VLP protein that still agglutinated RBCs.
###end p 36
###begin title 37
Viral-Like Particles
###end title 37
###begin p 38
###xml 445 446 445 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 670 671 670 671 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 871 872 871 872 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 987 988 981 982 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1583 1592 1571 1580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000368.s001">Figure S1</xref>
###xml 35 43 <span type="species:ncbi:10632">JC virus</span>
Genes encoding the VP1protein from JC virus strains BAE00117, AAT09831 and AAQ88264 were created synthetically and cloned into the Gateway pDEST8 (Invitrogen) shuttle vector for transfer into the pFASTBAC baculovirus expression system for baculovirus expression in SF9 cells. Purification of VLPs was performed from roughly 100 grams of frozen cell pellets from 5 liters of culture. Cells were resuspended in 500 ml of PBS containing 0.1 mM CaCl2. The cells are disrupted by passing the cell suspension twice through a Microfuidics Microfluidizer. Cell debris was removed by pelleting at 8000xG for 15 minutes. The supernatant volume was adjusted to 720 ml with PBS/CaCl2 and loaded onto 5 ml 40% sucrose cushions. Virus-like particles were twice pelleted through the sucrose cushions in a SW28 rotor at 100,000xG for 5 hours. The VLP pellets were resuspended in PBS/CaCl2 and then treated with 0.25% deoxycholate for 1 hour at 37degreesC followed by the addition of 4 M NaCl/0.1 mM CaCl2 for 1 hour at 4degreesC. Precipitated material was removed by centrifugation at 8000xG for 15 minutes. The resulting supernatant was concentrated and buffer exchanged by ultrafiltration through a Pelicon-2 500,000 MWCO membrane (Millipore). The concentrated VLPs were applied to the center of a 25-40% step gradient of Optiprep (Sigma) and banded at 190,000 g for 17 hours in a type 50.2 rotor. VLP bands were collected and then concentrated and buffer exchanged in an Amicon stirred cell with a 300,000 MWCO membrane. VLP quality was determined by gel electrophoresis and electron microscopy (Figure S1). Protein concentration was determined by the Micro BCA assay (Pierce). Electron microscopy was performed at the Department of Cell Biology at Harvard Medical School. VLP samples were placed on carbon grids, briefly washed in water and negatively stained with uranyl acetate and allowed to dry. The grids were viewed and imaged on a Technai G2 Spirit BioTWIN TEM.
###end p 38
###begin title 39
###xml 22 25 <span type="species:ncbi:10632">JCV</span>
Molecular Modeling of JCV VP1/Tetrasacharide Complex
###end title 39
###begin p 40
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Sali1">[40]</xref>
###xml 144 148 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Stehle1">[25]</xref>
###xml 367 371 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Stehle1">[25]</xref>
###xml 508 512 475 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000368-Brooks1">[41]</xref>
###xml 24 27 <span type="species:ncbi:10632">JCV</span>
###xml 390 393 <span type="species:ncbi:10632">JCV</span>
A homology model of the JCV VP1 protein pentameric unit was built with MODELER [40] using the structure of MPyV VP1 (Protein Data Bank ID: 1VPS [25] as a template. The model of NeuNAc-(alpha2,3)-Gal-(beta1,3)-[(alpha2,6)-NeuNAc]-Glc-NAc tetrasaccharide was build based on the structure of NeuNAc-(alpha2,3)-Gal-(beta1,3)-[(alpha2,6)-NeuNAc]-Glc-NAc bound to MPyV VP1 [25]. The model of the JCV VP1/NeuNAc-(alpha2,3)-Gal-(beta1,3)-[(alpha2,6)-NeuNAc]-Glc-NAc tetrasaccharide was extensively refined in CHARMM [41] and was analyzed using PyMOL visualization software (The PyMOL Molecular Graphics System (2002) DeLano Scientific, Palo Alto, CA, USA. ).
###end p 40
###begin title 41
Accession Numbers
###end title 41
###begin p 42
###xml 99 102 <span type="species:ncbi:10632">JCV</span>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
The National Center for Biotechnology Information (NCBI) () Protein database accession numbers for JCV VP1 sequences from non-PML patients.
###end p 42
###begin p 43
BAC66394, BAC66418, BAC66382, BAB11716, BAB11722, AAK28466, AAK28460, AAK28478, BAC66400, BAC66388, BAD06126, BAC66406, AAK97970, AAK97964, BAC81952, BAC81958, AAM89309, AAM89303, BAC81922, BAC81916, BAC81910, BAC81904, AAM89297, BAD11896, BAC81946, BAE45426, BAE45360, BAD06120, BAE45432, BAA01962, BAE45420, BAE45414, BAE45384, BAE45378, BAE45372, AAK98036, BAE45402, BAE45408, BAE45396, BAE45444, BAD06024, BAE75838, BAE75832, BAE75826, BAE75820, BAE75814, AAK98030, AAK98024, AAK98018, AAK98010, AAK98006, AAK98000, BAE45438, BAE45390, BAD06108, BAD06102, BAD06096, BAD06090, BAD06084, BAD06048, BAD06030, BAD06018, BAD06054, BAD06042, BAD06036, AAG30857, BAE45366, AAN85455, BAD06150, AAN85449, AAK98042, BAD06174, BAD06156, BAD06072, BAD06060, AAN85473, BAC81840, BAF40841, BAF40835, BAF40829, BAF40823, BAF40811, BAF40847, BAF40781, BAF40817, BAF40799, BAF40793, BAF40787, BAF40745, AAN85467, AAN85461, BAC81834, BAF40751, BAF40805, BAA01961, BAD98972, BAD98966, BAD06227, BAC66430, BAC66412, BAD91887, BAD21235, BAD27118, BAC66424, BAA01958, BAB11710, BAD21265, BAD21259, BAD21253, BAD21241, BAD21229, BAD21247, BAD21283, BAD21271, BAD21295, BAD21289, BAA01959, BAA01960, BAD11848, BAD11842, AAM89339, AAM89327, BAD11836, BAC81852, BAC81858, BAD06144, AAG37198, AAM89315, BAD06138, BAD11890, BAD11884, BAD11878, BAD11872, BAD11866, AAK97994, BAB11698, BAC81940, BAC81964, AAK97946, BAD06066, BAF40769, BAC81870, BAC81864, BAC81934, BAC66376, BAC81874, BAC81846, AAK97940, BAC81898, BAC81892, AAK97922, AAK97916, AAK97910, AAK97982, BAF40763, BAD06078, AAK97958, BAD11860, BAF40757, BAD06162, AAM89321, BAD11854, AAK97928, BAD11830, BAF40775, BAB11704, BAC81928, AAK97988, BAD11902, BAD11824, BAD06233, BAC81886, BAC81880, AAM89345, BAD06168, AAM89333, BAD06132, BAC82365, AAK97952, BAA01964, BAA01963, AAK97934, BAD06114, AAK97976, BAD21277, AAR13077, BAE02908, AAR12957, AAR02463, AAR02457, BAE03058, AAR89235, BAE02896, AAR89241, BAE02890, BAE03064, BAE03070, BAE03082, AAG34673, AAG34667, AAR89205, AAR89217, AAR13659, BAE03088, BAE03160, AAQ88264, AAR89187, AAR89283, AAK28472, AAR06661, AAR89253, AAR89247, AAR89199, AAR89193, AAR89229, AAR89223, AAR89265, AAR32743, AAR89277, BAE03166, BAE02920, BAE02914, BAE03112, BAE03106, BAE03100, BAE03094, BAE03076, BAE02944, BAE02998, BAE02992, BAE02986, BAE02980, BAE02974, BAE02968, BAE02962, BAE03016, BAE02902, BAE03040, AAR89211, AAR89271, BAE02956, BAE02938, BAE02932, BAE03148, BAE02950, BAE03004, BAE03154, BAE03142, BAE03136, BAE03130, BAE03124, BAE03118, BAE02926.
###end p 43
###begin title 44
Supporting Information
###end title 44
###begin p 45
Electron micrographs of Virus Like Particles (VLP) used in hemagglutination assay. Purified VLP samples were placed on carbon grids, briefly washed in water and negatively stained with uranyl acetate and allowed to dry. The grids were viewed and imaged on a Technai G2 Spirit BioTWIN TEM.electron microscope. The magnification bar represents 100 nm.
###end p 45
###begin p 46
(0.43 MB TIF)
###end p 46
###begin p 47
Click here for additional data file.
###end p 47
###begin p 48
###xml 0 3 <span type="species:ncbi:10632">JCV</span>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
JCV VP1 sequences from PML patients.
###end p 48
###begin p 49
(0.34 MB DOC)
###end p 49
###begin p 50
Click here for additional data file.
###end p 50
###begin p 51
###xml 26 29 <span type="species:ncbi:10632">JCV</span>
Amino acid variability of JCV VP1 sequences.
###end p 51
###begin p 52
(0.11 MB DOC)
###end p 52
###begin p 53
Click here for additional data file.
###end p 53
###begin p 54
###xml 26 29 <span type="species:ncbi:10632">JCV</span>
Amino acid variability of JCV VP1 sequences between VLPs.
###end p 54
###begin p 55
(0.03 MB DOC)
###end p 55
###begin p 56
Click here for additional data file.
###end p 56
###begin p 57
We would like to thank Guohui Li and John Carulli for helpful discussions and Maria Ericsson of the Harvard Medical School Electron Microscopy Facility for assistance with electron microscopic characterization of VLPs. We are also grateful to Phoebe Roberts and Katya Mantrova for help with the references.
###end p 57
###begin title 58
References
###end title 58
###begin article-title 59
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 55 63 <span type="species:ncbi:10629">BK virus</span>
###xml 65 68 <span type="species:ncbi:10629?0.9737827715355806">BKV</span>
###xml 74 82 <span type="species:ncbi:10632">JC virus</span>
###xml 84 87 <span type="species:ncbi:10632">JCV</span>
Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV).
###end article-title 59
###begin article-title 60
Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare.
###end article-title 60
###begin article-title 61
###xml 80 83 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
###end article-title 61
###begin article-title 62
###xml 0 8 <span type="species:ncbi:10632">JC virus</span>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
JC virus regulatory region tandem repeats in plasma and central nervous system isolates correlate with poor clinical outcome in patients with progressive multifocal leukoencephalopathy.
###end article-title 62
###begin article-title 63
###xml 86 94 <span type="species:ncbi:10632">JC virus</span>
###xml 132 137 <span type="species:ncbi:9606">human</span>
Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.
###end article-title 63
###begin article-title 64
###xml 49 64 <span type="species:ncbi:10632">polyomavirus JC</span>
DNA rearrangements in organ-specific variants of polyomavirus JC strain GS.
###end article-title 64
###begin article-title 65
###xml 59 67 <span type="species:ncbi:10632">JC virus</span>
Differences in regulatory sequences of naturally occurring JC virus variants.
###end article-title 65
###begin article-title 66
###xml 53 68 <span type="species:ncbi:10632">JC polyomavirus</span>
New sequence polymorphisms in the outer loops of the JC polyomavirus major capsid protein (VP1) possibly associated with progressive multifocal leukoencephalopathy.
###end article-title 66
###begin article-title 67
###xml 60 75 <span type="species:ncbi:10632">JC polyomavirus</span>
Characterization of the VP1 loop mutations widespread among JC polyomavirus isolates associated with progressive multifocal leukoencephalopathy.
###end article-title 67
###begin article-title 68
###xml 69 77 <span type="species:ncbi:10632">JC virus</span>
Lack of disease-specific amino acid changes in the viral proteins of JC virus isolates from the brain with progressive multifocal leukoencephalopathy.
###end article-title 68
###begin article-title 69
Quantitative biochemical rationale for differences in transmissibility of 1918 pandemic influenza A viruses.
###end article-title 69
###begin article-title 70
###xml 27 32 <span type="species:ncbi:9606">human</span>
Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin.
###end article-title 70
###begin article-title 71
Genetic and structural analysis of a virulence determinant in polyomavirus VP1.
###end article-title 71
###begin article-title 72
###xml 113 118 <span type="species:ncbi:10090">mouse</span>
Discrimination between sialic acid-containing receptors and pseudoreceptors regulates polyomavirus spread in the mouse.
###end article-title 72
###begin article-title 73
###xml 28 32 <span type="species:ncbi:10090">mice</span>
Polyomavirus replication in mice: influences of VP1 type and route of inoculation.
###end article-title 73
###begin article-title 74
A single-amino-acid substitution in polyomavirus VP1 correlates with plaque size and hemagglutination behavior.
###end article-title 74
###begin article-title 75
A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood.
###end article-title 75
###begin article-title 76
Evaluation of the maximum likelihood estimate of the evolutionary tree topologies from DNA sequence data, and the branching order in hominoidea.
###end article-title 76
###begin article-title 77
A Hidden Markov Model approach to variation among sites in rate of evolution.
###end article-title 77
###begin article-title 78
Detecting isolation by distance using phylogenies of genes.
###end article-title 78
###begin article-title 79
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 58 73 <span type="species:ncbi:10632">polyomavirus JC</span>
Phylogenetic analysis of 22 complete genomes of the human polyomavirus JC virus.
###end article-title 79
###begin article-title 80
###xml 13 21 <span type="species:ncbi:10632">JC virus</span>
Genotypes of JC virus in East, Central and Southwest Europe.
###end article-title 80
###begin article-title 81
PAML: a program package for phylogenetic analysis by maximum likelihood.
###end article-title 81
###begin article-title 82
Spidermonkey: rapid detection of co-evolving sites using Bayesian graphical models.
###end article-title 82
###begin article-title 83
High-resolution structure of a polyomavirus VP1-oligosaccharide complex: implications for assembly and receptor binding.
###end article-title 83
###begin article-title 84
###xml 59 79 <span type="species:ncbi:10794">minute virus of mice</span>
Identification of the sialic acid structures recognized by minute virus of mice and the role of binding affinity in virulence adaptation.
###end article-title 84
###begin article-title 85
Accuracy and power of the likelihood ratio test in detecting adaptive molecular evolution.
###end article-title 85
###begin article-title 86
Accuracy and power of bayes prediction of amino acid sites under positive selection.
###end article-title 86
###begin article-title 87
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 38 53 <span type="species:ncbi:10632">polyomavirus JC</span>
Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha(2-6)-linked sialic acids.
###end article-title 87
###begin article-title 88
###xml 38 43 <span type="species:ncbi:9606">human</span>
Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy.
###end article-title 88
###begin article-title 89
###xml 49 57 <span type="species:ncbi:10632">JC virus</span>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Detection of the archetypal regulatory region of JC virus from the tonsil tissue of patients with tonsillitis and tonsilar hypertrophy.
###end article-title 89
###begin article-title 90
###xml 13 21 <span type="species:ncbi:10632">JC virus</span>
###xml 29 34 <span type="species:ncbi:9606">human</span>
Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection.
###end article-title 90
###begin article-title 91
###xml 33 41 <span type="species:ncbi:10632">JC virus</span>
###xml 78 83 <span type="species:ncbi:9606">human</span>
Differential distribution of the JC virus receptor-type sialic acid in normal human tissues.
###end article-title 91
###begin article-title 92
###xml 46 81 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 132 140 <span type="species:ncbi:10632">JC virus</span>
Progressive multifocal leukoencephalopathy in human immunodeficiency virus type 1-infected patients: absence of correlation between JC virus neurovirulence and polymorphisms in the transcriptional control region and the major capsid protein loci.
###end article-title 92
###begin article-title 93
###xml 2 8 <span type="species:ncbi:13443">Coffee</span>
T-Coffee: A novel method for fast and accurate multiple sequence alignment.
###end article-title 93
###begin article-title 94
Datamonkey: rapid detection of selective pressure on individual sites of codon alignments.
###end article-title 94
###begin article-title 95
HyPhy: hypothesis testing using phylogenies.
###end article-title 95
###begin article-title 96
###xml 75 80 <span type="species:ncbi:9606">human</span>
###xml 81 96 <span type="species:ncbi:10632">polyomavirus JC</span>
Comparison of real-time PCR and hemagglutination assay for quantitation of human polyomavirus JC.
###end article-title 96
###begin article-title 97
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 47 55 <span type="species:ncbi:10632">JC virus</span>
Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy.
###end article-title 97
###begin article-title 98
Comparative protein modelling by satisfaction of spatial restraints.
###end article-title 98
###begin article-title 99
CHARMM: A program for macromolecular energy, minimization, and dynamics calculations.
###end article-title 99
###begin p 100
In the interests of transparency and to help readers to form their own judgements of potential bias, we would like to declare potential competing interests as Alexey Lugovskoy, Kenneth Simon, and Leonid Gorelik are currently employed by and possess shares of Biogen IDEC Inc; Shamil R. Sunyaev has a consulting agreement with Biogen IDEC Inc.
###end p 100
###begin p 101
Biogen IDEC Inc funded the current study. Biogen Idec employees (Leonid Gorelik, Alexey Lugovskoy and Kenneth Simon) planned, designed, conducted and analysed, interpreted experiments described in the study. Biogen Idec employees (Leonid Gorelik, Alexey Lugovskoy and Kenneth Simon) also took part in preparation and review of the manuscript.
###end p 101

